Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

at Yale University and is board certified in Neurology.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 study in patients with refractory solid tumors.

Nektar technology is used in nine approved partnered products in the U.S. or Europe today, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's technology platform, Nektar's pipeline of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... York (PRWEB) July 25, 2014 According ... Research, "Biological Drugs Market - Global Industry Analysis, Size, ... global biological drugs market is estimated at USD 161,056.5 ... a CAGR of 10.1% from 2014 to 2020, to ... 2020. , The biological drugs market is witnessing a ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 At the request ... granted a 60-day extension for the public comment period ... Rule for Model Aircraft established by Congress as part ... The 60-day extension establishes the new deadline for comments ... Department of Transportation/FAA notice published in the Federal Register ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the Third Quarter 2007 financial results.,Michael S. ... will,host the call. Keryx will announce its financial results ... prior to the call. In order to participate ...
... Positive Phase I Results for R1507, COPENHAGEN, October ... from a Phase I study of R1507 in patients,with ... a human,monoclonal antibody targeting the insulin-like growth factor receptor,(IGF-1R) ... Nine of 34 adult patients with solid tumors experienced ...
... Calif., Oct. 23 InVitria has released ... factor for cell culture,media outperforms transferrin and ... Because Lacromin is produced in a completely,animal-free ... over,animal-derived alternatives including bovine and human transferrin. ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 3InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin 2
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... diffusion tensor tractography (DTT), which is derived from ... for three motor tracts, such as the corticospinal ... became possible. The corticospinal tract is known to ... in the human brain. Several studies have reported ... herniation. In addition, some studies have demonstrated recovery ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Bacteria manipulate salt to build shelters to hibernate 2
... 2, 2014 EcoHealth Alliance, a nonprofit organization ... issues, and Bat Conservation International, which works to ... are joining forces in formal partnership. The organizations ... and public health programs that enhance outreach with ...
... N.C. A new Duke University-led study has documented dramatic, ... estuary. "The natural short-term variability in acidity ... global predictions for the ocean as a whole and may ... organisms, particularly shelled organisms that are especially susceptible to changes ...
... centuries as a pain reliever in Chinese medicine may be ... chronic pain. A key pain-relieving ingredient is a compound known ... plant Corydalis , a member of the poppy family, ... Press journal Current Biology on January 2. ...
Cached Biology News:EcoHealth Alliance and Bat Conservation International forge partnership to work on global bat conservation and public health issues 2Local factors cause dramatic spikes in coastal ocean acidity 2Plant used in Chinese medicine fights chronic pain 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: